1. R. Levi,Cardiac anaphylaxis: Models, mediators, mechanisms, and clinical considerations. InHuman inflammatory disease, clinical immunology, vol. 1. pp. 93–105 (Eds. G. Marone, L. M. Lichtenstein, M. Condorelli and A. S. Fauci) B. C. Decker, Inc., Toronto 1988.
2. H. Anhut, W. Bernauer and B. A. PeskarRadioimmunological determination of thromboxane release in cardiac anaphylaxis. Europ. J. Pharmacol.44, 85–88 (1977).
3. G. Allan and R. Levi,Thromboxane, and prostacyclin release during cardiac immediate hypersensitivity reactions in vitro. J. Pharmacol. Exp. Ther.217, 157–161 (1988).
4. U. Aehringhaus, B. A. Peskar, H. R. Wittenberg and R. H. Wölbling,Effect of inhibition of synthesis and receptor antagonism of SRS-A in cardiac anaphylaxis. Br. J. Pharmacol.80, 73–80 (1983).
5. P. Weinerowski, G. Wittmann, U. Aehringhaus and B. A. Peskar,Pharmacological modification of leukotriene release and coronary constrictor effect in cardiac anaphylaxis. InAdvances in prostaglandin, thromboxane and leukotriene research, vol. 13. pp. 47–50 (Ed. G. G. Neri Serneri) Raven Press, New York 1985.